Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 143840
Corporate User License Price USD 6000
Corporate User License Price INR 431520
Site License Price USD 4000
Site License Price INR 287680
Request a Quote

Report Title

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Review, H2 2016

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Review, H2 2016


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Review, H2 2016

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Review, H2 2016



Executive Summary

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Review, H2 2016', provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

The report reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics and enlists all their major and minor projects

The report assesses Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Overview 9

Therapeutics Development 10

Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Overview 10

Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Comparative Analysis 11

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Therapeutics under Development by Companies 12

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Therapeutics under Investigation by Universities/Institutes 15

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Products under Development by Companies 19

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Products under Investigation by Universities/Institutes 23

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Companies Involved in Therapeutics Development 24

4SC AG 24

AbbVie Inc 25

Acetylon Pharmaceuticals, Inc. 26

Actinium Pharmaceuticals, Inc. 27

ADC Therapeutics Sarl 28

Affimed GmbH 29

Amgen Inc. 30

Arno Therapeutics, Inc. 31

Bellicum Pharmaceuticals, Inc. 32

Bristol-Myers Squibb Company 33

Celgene Corporation 34

Cell Medica Limited 35

Cellular Biomedicine Group, Inc. 36

Constellation Pharmaceuticals, Inc. 37

Curis, Inc. 38

Faron Pharmaceuticals Oy 39

Gamida Cell Ltd. 40

Incyte Corporation 41

Merck & Co., Inc. 42

Merck KGaA 43

Mesoblast Limited 44

Millennium Pharmaceuticals Inc 45

Mirati Therapeutics Inc. 46

Molecular Templates Inc. 47

NantKwest, Inc. 48

Ono Pharmaceutical Co., Ltd. 49

Pfizer Inc. 50

Philogen S.p.A. 51

Polyphor Ltd. 52

Rich Pharmaceuticals, Inc. 53

Seattle Genetics, Inc. 54

Selvita S.A. 55

Sigma-Tau S.p.A. 56

Spectrum Pharmaceuticals, Inc. 57

Stemline Therapeutics, Inc. 58

Taiwan Liposome Company, Ltd. 59

Takeda Pharmaceutical Company Limited 60

TG Therapeutics, Inc. 61

Theravectys SA 62

TRACON Pharmaceuticals, Inc. 63

Trillium Therapeutics Inc. 64

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Therapeutics Assessment 65

Assessment by Monotherapy Products 65

Assessment by Combination Products 66

Assessment by Target 67

Assessment by Mechanism of Action 72

Assessment by Route of Administration 78

Assessment by Molecule Type 80

Drug Profiles 82

(INCB-039110 + INCB-040093)-Drug Profile 82

ADCT-301-Drug Profile 83

AFM-13-Drug Profile 84

Alocrest-Drug Profile 88

AR-42-Drug Profile 90

avelumab-Drug Profile 92

azacitidine-Drug Profile 97

balixafortide-Drug Profile 102

BC-8Y90-Drug Profile 104

BMS-986016-Drug Profile 105

BPX-501-Drug Profile 107

brentuximab vedotin-Drug Profile 111

CBM-C30.1-Drug Profile 135

Cellular Immunotherapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma-Drug Profile 136

Cellular Immunotherapy for Oncology-Drug Profile 137

Cellular Immunotherapy for Oncology-Drug Profile 138

Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas-Drug Profile 139

Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas-Drug Profile 140

Cellular Immunotherapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia-Drug Profile 141

Cellular Immunotherapy to Target GM-CSF for Solid Tumor and Hematological Cancer-Drug Profile 142

Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection-Drug Profile 143

Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases-Drug Profile 144

Cellular Immunotherapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology-Drug Profile 145

CMD-003-Drug Profile 146

CPI-0610-Drug Profile 148

CUDC-907-Drug Profile 149

Epstein-Barr virus vaccine-Drug Profile 154

Ferritarg-Drug Profile 155

FP-1305-Drug Profile 156

haNK Program-Drug Profile 158

ibrutinib-Drug Profile 159

INCB-40093-Drug Profile 184

Indimitecan-Drug Profile 185

Indotecan hydrochloride-Drug Profile 186

Iomab-B-Drug Profile 187

ipilimumab-Drug Profile 192

ixazomib citrate-Drug Profile 200

lirilumab-Drug Profile 209

MK-2206-Drug Profile 213

mocetinostat-Drug Profile 216

Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections-Drug Profile 221

MPC-CBE-Drug Profile 222

MT-17000-Drug Profile 224

NiCord-Drug Profile 225

nivolumab-Drug Profile 228

NL-101-Drug Profile 256

ONX-0801-Drug Profile 258

pembrolizumab-Drug Profile 260

PF-06801591-Drug Profile 291

PNK-007-Drug Profile 292

procarbazine hydrochloride-Drug Profile 293

radretumab-Drug Profile 294

resminostat-Drug Profile 296

ricolinostat-Drug Profile 306

RP-323-Drug Profile 314

ruxolitinib phosphate-Drug Profile 316

sapanisertib-Drug Profile 328

SEA-CD40-Drug Profile 331

SEL-24B489-Drug Profile 332

SL-101-Drug Profile 333

SL-501-Drug Profile 334

Small Molecule to Inhibit ADAM-10 for Hodgkin Lymphoma-Drug Profile 335

temsirolimus-Drug Profile 336

TGR-1202-Drug Profile 338

TRC-102-Drug Profile 345

TTI-621-Drug Profile 347

Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma-Drug Profile 350

vinorelbine tartrate-Drug Profile 351

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Dormant Projects 352

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Discontinued Products 356

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Product Development Milestones 357

Featured News & Press Releases 357

Appendix 370

Methodology 370

Coverage 370

Secondary Research 370

Primary Research 370

Expert Panel Validation 370

Contact Us 370

Disclaimer 371

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Tables

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2016 15

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Development, H2 2016 23

Products under Development by Companies, H2 2016 24

Products under Development by Companies, H2 2016 (Contd..1) 25

Products under Development by Companies, H2 2016 (Contd..2) 26

Products under Development by Companies, H2 2016 (Contd..3) 27

Products under Investigation by Universities/Institutes, H2 2016 28

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by 4SC AG, H2 2016 29

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by AbbVie Inc, H2 2016 30

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 31

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Actinium Pharmaceuticals, Inc., H2 2016 32

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by ADC Therapeutics Sarl, H2 2016 33

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Affimed GmbH , H2 2016 34

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Amgen Inc., H2 2016 35

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Arno Therapeutics, Inc., H2 2016 36

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 37

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Bristol-Myers Squibb Company, H2 2016 38

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Celgene Corporation, H2 2016 39

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Cell Medica Limited, H2 2016 40

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Cellular Biomedicine Group, Inc., H2 2016 41

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Constellation Pharmaceuticals, Inc., H2 2016 42

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Curis, Inc., H2 2016 43

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Faron Pharmaceuticals Oy, H2 2016 44

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Gamida Cell Ltd., H2 2016 45

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Incyte Corporation, H2 2016 46

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Merck & Co., Inc., H2 2016 47

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Merck KGaA, H2 2016 48

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Mesoblast Limited, H2 2016 49

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Millennium Pharmaceuticals Inc, H2 2016 50

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Mirati Therapeutics Inc., H2 2016 51

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Molecular Templates Inc., H2 2016 52

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by NantKwest, Inc., H2 2016 53

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 54

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Pfizer Inc., H2 2016 55

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Philogen S.p.A., H2 2016 56

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Polyphor Ltd., H2 2016 57

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Rich Pharmaceuticals, Inc., H2 2016 58

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Seattle Genetics, Inc., H2 2016 59

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Selvita S.A., H2 2016 60

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Sigma-Tau S.p.A., H2 2016 61

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 62

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Stemline Therapeutics, Inc., H2 2016 63

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Taiwan Liposome Company, Ltd., H2 2016 64

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 65

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by TG Therapeutics, Inc., H2 2016 66

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Theravectys SA, H2 2016 67

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by TRACON Pharmaceuticals, Inc., H2 2016 68

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline by Trillium Therapeutics Inc., H2 2016 69

Assessment by Monotherapy Products, H2 2016 70

Assessment by Combination Products, H2 2016 71

Number of Products by Stage and Target, H2 2016 73

Number of Products by Stage and Mechanism of Action, H2 2016 78

Number of Products by Stage and Route of Administration, H2 2016 83

Number of Products by Stage and Molecule Type, H2 2016 85

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Dormant Projects, H2 2016 356

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Dormant Projects (Contd..1), H2 2016 357

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Dormant Projects (Contd..2), H2 2016 358

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Dormant Projects (Contd..3), H2 2016 359

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Discontinued Products, H2 2016 360

List of Figures

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2016 15

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Products, H2 2016 23

Assessment by Monotherapy Products, H2 2016 70

Number of Products by Top 10 Targets, H2 2016 72

Number of Products by Stage and Top 10 Targets, H2 2016 72

Number of Products by Top 10 Mechanism of Actions, H2 2016 77

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 77

Number of Products by Routes of Administration, H2 2016 82

Number of Products by Stage and Routes of Administration, H2 2016 82

Number of Products by Top 10 Molecule Types, H2 2016 84

Number of Products by Stage and Top 10 Molecule Types, H2 2016 84

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

4SC AG

AbbVie Inc

Acetylon Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ADC Therapeutics Sarl

Affimed GmbH

Amgen Inc.

Arno Therapeutics, Inc.

Bellicum Pharmaceuticals, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

Cell Medica Limited

Cellular Biomedicine Group, Inc.

Constellation Pharmaceuticals, Inc.

Curis, Inc.

Faron Pharmaceuticals Oy

Gamida Cell Ltd.

Incyte Corporation

Merck & Co., Inc.

Merck KGaA

Mesoblast Limited

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc.

Molecular Templates Inc.

NantKwest, Inc.

Ono Pharmaceutical Co., Ltd.

Pfizer Inc.

Philogen S.p.A.

Polyphor Ltd.

Rich Pharmaceuticals, Inc.

Seattle Genetics, Inc.

Selvita S.A.

Sigma-Tau S.p.A.

Spectrum Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.

Taiwan Liposome Company, Ltd.

Takeda Pharmaceutical Company Limited

TG Therapeutics, Inc.

Theravectys SA

TRACON Pharmaceuticals, Inc.

Trillium Therapeutics Inc.

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Therapeutic Products under Development, Key Players in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Therapeutics, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Overview, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand